Hepatology Research最新文献

Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact. 自身免疫性肝炎中广泛的肌肉损失及其不良预后影响

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-09 DOI: 10.1111/hepr.70203

Tomoko Tadokoro, Asahiro Morishita, Takushi Manabe, Hiroki Tai, Rie Yano, Mai Nakahara, Kyoko Oura, Koji Fujita, Shima Mimura, Joji Tani, Hideki Kobara

{"title":"Widespread Muscle Loss in Autoimmune Hepatitis and Its Adverse Prognostic Impact.","authors":"Tomoko Tadokoro, Asahiro Morishita, Takushi Manabe, Hiroki Tai, Rie Yano, Mai Nakahara, Kyoko Oura, Koji Fujita, Shima Mimura, Joji Tani, Hideki Kobara","doi":"10.1111/hepr.70203","DOIUrl":"https://doi.org/10.1111/hepr.70203","url":null,"abstract":"Aim: Reports on the prevalence of sarcopenia in patients with autoimmune hepatitis (AIH) are limited, and its association with prognosis remains unclear. Therefore, we evaluated sarcopenia-related factors and their prognostic impact associated with AIH and compared these findings with those of patients with primary biliary cholangitis (PBC).Methods: We retrospectively analyzed 161 patients with AIH or PBC who were followed up at our institution and underwent computed tomography (CT) between January 2004 and February 2025. Data on sex, age, comorbidities, sarcopenia-related factors, treatment, cirrhosis, and clinical outcomes were reviewed. Patients with the PBC-AIH overlap syndrome or concomitant malignancy were excluded. Sarcopenia was assessed using the psoas muscle mass index (PMI) on CT.Results: A total of 67 and 94 patients had AIH and PBC, respectively. The two groups showed no significant differences in the proportion of males, 5-year survival, or the prevalence of cirrhosis at diagnosis and other autoimmune diseases. A low PMI was observed in 32.8% and 17.0% of patients with AIH and PBC, respectively, and was significantly more frequent in patients with AIH (p = 0.02). Among patients with AIH, those with a low PMI had significantly poorer survival than those without it. Factors associated with poor prognosis in patients with AIH included a higher model for the end-stage liver disease (MELD) score, low PMI, and the presence of cirrhosis.Conclusion: CT-based assessment of PMI in patients with AIH may provide supplementary prognostic information for risk stratification at diagnosis.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variability in Liver Disease Progression and Outcomes in Glycogen Storage Disease Type IV. 糖原储存病IV型肝病进展和结局的变异性

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-07 DOI: 10.1111/hepr.70201

Rebecca L Koch, William R Jeck, Priya S Kishnani

引用次数: 0

Letter to the Editor: "Surgical Resections for Hepatocellular Carcinomas Arising From Fontan-Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies". 致编辑的信：“丰坦相关肝病引起的肝细胞癌的手术切除；开放、腹腔镜和机器人肝切除术”。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-04 DOI: 10.1111/hepr.70192

Linfeng Sun, Wei Shao

引用次数: 0

From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell-free DNA in Metabolic Dysfunction-Associated Steatotic Liver Disease. 从基因组不稳定性到表观遗传特征：代谢功能障碍相关脂肪变性肝病中循环无细胞DNA的演变景观。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-02 DOI: 10.1111/hepr.70198

Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Shamsul Mohd Zain

{"title":"From Genomic Instability to Epigenetic Signatures: The Evolving Landscape of Circulating Cell-free DNA in Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Wei-Yue Lim, Rosmawati Mohamed, Yuh-Fen Pung, Shamsul Mohd Zain","doi":"10.1111/hepr.70198","DOIUrl":"https://doi.org/10.1111/hepr.70198","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a leading global health burden, yet its diagnosis and staging rely heavily on invasive liver biopsies. Liquid biopsy, utilizing circulating cell-free DNA (cfDNA), offers a promising noninvasive alternative to capture hepatic genomic instability. This review consolidates current knowledge on cfDNA biomarkers in MASLD, moving from established quantitative metrics to emerging epigenetic insights. The role of mitochondrial DNA copy number (mtDNAcn) is examined as a dynamic marker of oxidative stress, highlighting its biphasic response: compensatory upregulation in early disease versus depletion in advanced fibrosis. Furthermore, key nuclear copy number variations (CNVs) specifically the XPO4 duplication (13q12.11), CES1 deletion (16q12.2), and ACOT1 deletion (14q24.3) are discussed regarding their mechanistic drivers of fibrogenesis and lipid metabolism dysregulation. Addressing the complexity of MASLD pathogenesis, the discussion extends to emerging multi-modal metrics, including DNA methylation and fragmentomics. These modalities offer superior specificity by tracing the \"tissue of origin\" and distinguishing apoptotic from necrotic fragmentation patterns, effectively addressing the diagnostic challenges posed by the \"burnout\" phenomenon in advanced cirrhosis. Finally, critical future directions are outlined, emphasizing the necessity for standardized pre-analytical protocols and the integration of multi-omics data with machine learning. This comprehensive approach will shed light on the transition cfDNA from a research tool to a precise clinical instrument for early risk stratification and therapeutic monitoring.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ALDH2 Polymorphism in Alcohol-Related Cirrhosis Requiring Liver Transplantation: A Recipient-Donor Analysis. 酒精相关性肝硬化需要肝移植的ALDH2多态性：受体-供体分析

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-02 DOI: 10.1111/hepr.70200

Noriyo Yamashiki, Yoshihide Ueda, Takashi Ito, Etsuro Hatano

{"title":"ALDH2 Polymorphism in Alcohol-Related Cirrhosis Requiring Liver Transplantation: A Recipient-Donor Analysis.","authors":"Noriyo Yamashiki, Yoshihide Ueda, Takashi Ito, Etsuro Hatano","doi":"10.1111/hepr.70200","DOIUrl":"https://doi.org/10.1111/hepr.70200","url":null,"abstract":"Aim: Genetic polymorphisms of alcohol-metabolizing enzymes influence drinking behavior and susceptibility to alcohol-related liver disease (ALD). This study aimed to clarify the distribution of ALDH2 and ADH1B genotypes in liver transplant recipients with ALD, and to explore associations with post-transplant drinking behavior using a recipient-donor paired design.Methods: Twenty-four living donor liver transplant (LDLT) recipients with ALD, their corresponding living donors, and 50 healthy controls were analyzed. Single nucleotide polymorphisms of ALDH2 (rs671) and ADH1B (rs1229984) were determined by the Cycleave PCR method. Drinking behavior before and after transplantation was assessed by self-report and electronic health records. Post-transplant alcohol use was classified as habitual (≥ once per week) or occasional (< once per week).Results: ALDH2 genotype distribution differed among three groups (p = 0.002), with enrichment of the ALDH2*1/*1 genotype in ALD recipients (92%). ADH1B genotype distribution also differed among groups (p = 0.041), although the effect size was modest. During a median follow-up of 5.3 years (range, 0.3-15.9 years), 11 recipients (45%) reported post-transplant alcohol use, including 5 habitual drinkers (20%). In an exploratory analysis, a non-significant trend toward higher rates of habitual drinking was observed among recipients who received grafts from donors with the ALDH2*1/*1 genotype compared with other genotypes (40% vs. 7%, p = 0.12).Conclusions: The ALDH2*1/*1 genotype was more prevalent among liver transplant recipients with alcohol-related cirrhosis than among donors or healthy controls, supporting a role of alcohol tolerance-related genetic background in progression to end-stage liver disease. Donor ALDH2 genotypes may also influence post-transplant drinking behavior in an exploratory manner.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Liver Transplantation in Japan: Registry by the Japanese Liver Transplantation Society. 日本肝移植：日本肝移植协会注册。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-01 Epub Date: 2026-04-09 DOI: 10.1111/hepr.70170

Koji Umeshita, Susumu Eguchi, Takumi Fukumoto, Hironori Haga, Kiyoshi Hasegawa, Mureo Kasahara, Shigeyuki Kawachi, Satoshi Mochida, Hiroaki Nagano, Yuji Soejima, Yasutsugu Takada, Yoshihide Ueda, Takehiro Noda, Hidetoshi Eguchi, Hideki Ohdan

{"title":"Liver Transplantation in Japan: Registry by the Japanese Liver Transplantation Society.","authors":"Koji Umeshita, Susumu Eguchi, Takumi Fukumoto, Hironori Haga, Kiyoshi Hasegawa, Mureo Kasahara, Shigeyuki Kawachi, Satoshi Mochida, Hiroaki Nagano, Yuji Soejima, Yasutsugu Takada, Yoshihide Ueda, Takehiro Noda, Hidetoshi Eguchi, Hideki Ohdan","doi":"10.1111/hepr.70170","DOIUrl":"10.1111/hepr.70170","url":null,"abstract":"As of December 31, 2023, a total of 11,731 liver transplants were performed in 70 institutions in Japan. There were 922 deceased donor transplants (919 from heart-beating donors and 3 from non-heart-beating donors) and 10,809 living-donor transplants. The annual total of liver transplants in 2023 was 470. Deceased-donor transplants increased to 118 in 2023 from 86 in 2022. The most frequent indication was cholestatic disease, followed by hepatocellular disease and neoplastic disease. As for hepatocellular disease in 2023, alcoholic cirrhosis and non-alcoholic steatohepatitis were the most common. Five patients underwent so-called dual graft living-donor liver transplantation (1 in 2001, 1 in 2006, and 3 in 2023). Patient survival following transplantation from heart-beating donors (919 transplants: 1-year 89.1%, 3-year 86.8%, 5-year 84.0%, 10-year 76.6%, 15-year 68.9%, and 20-year 57.7%) was similar to that from living-donors (10,809 transplants: 1-year 86.1%, 3-year 82.4%, 5-year 80.0%, 10-year 75.0%, 15-year 70.1%, 20-year 65.3%, 25-year 61.9%, and 30-year 59.5%). Graft survival was very much the same as patient survival (heart-beating donor: 1-year 88.5%, 3-year 86.1%, 5-year 83.2%, 10-year 75.8%, 15-year 68.2%, and 20-year 53.8% and living-donor: 1-year 85.5%, 3-year 81.5%, 5-year 78.9%, 10-year 73.3%, 15-year 68.0%, 20-year 62.8%, 25-year 59.3%, and 30-year 56.7%). Survival data are reported according to age and sex of recipient, indication, graft type, age and sex of donor, ABO-compatibility, and other factors. Cause of death of living liver donors is also reported.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"662-682"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147645053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Outcomes and Transitional Care Following Endoscopic Variceal Treatment in Pediatric Portal Hypertension. 内镜下静脉曲张治疗儿童门静脉高压症的临床结果和过渡性护理。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-01 Epub Date: 2026-01-08 DOI: 10.1111/hepr.70117

Akira Uchiyama, Shunhei Yamashina, Satoshi Sakuma, Masahiro Tada, Kei Ishizuka, Maki Morinaga, Hiroo Fukada, Reiko Yaginuma, Kyoko Fukuhara, Mitsuyoshi Suzuki, Kazuyoshi Kon, Go Miyano, Hiromichi Shoji, Kenichi Ikejima

{"title":"Clinical Outcomes and Transitional Care Following Endoscopic Variceal Treatment in Pediatric Portal Hypertension.","authors":"Akira Uchiyama, Shunhei Yamashina, Satoshi Sakuma, Masahiro Tada, Kei Ishizuka, Maki Morinaga, Hiroo Fukada, Reiko Yaginuma, Kyoko Fukuhara, Mitsuyoshi Suzuki, Kazuyoshi Kon, Go Miyano, Hiromichi Shoji, Kenichi Ikejima","doi":"10.1111/hepr.70117","DOIUrl":"10.1111/hepr.70117","url":null,"abstract":"Background: Esophagogastric variceal (EGV) bleeding is a serious complication of pediatric-onset liver disease; however, evidence regarding endoscopic management and long-term outcomes remains limited. This study aimed to evaluate clinical outcomes following endoscopic therapy for pediatric EGV and to clarify challenges related to adherence and transitional care.Methods: We retrospectively reviewed patients with pediatric-onset liver disease who underwent endoscopic treatment for EGV between 2012 and 2024. Patients were categorized into a childhood group (≤ 15 years) and a young adult group (> 15 years). Clinical characteristics, treatment outcomes, retreatment, survival, and adherence during the transition to adult care were analyzed.Results: Emergency endoscopy for hematemesis was common in the childhood group. Despite frequent recurrence, endoscopic therapy was effective and no rebleeding or deaths occurred. In contrast, young adults showed significantly poorer survival (1-year 84.6%; 2-year 69.2%; and p = 0.045), primarily due to hepatic decompensation. Nearly half self-discontinued follow-up during the transition period, and nonadherence was associated with higher Child-Pugh and MELD scores and markedly reduced survival (5-year 33.3% and p = 0.038). Some young adults later developed alcohol-related liver disease, with significantly worse outcomes than the childhood group (p = 0.023).Conclusions: Endoscopic therapy is effective and safe for pediatric EGV, although recurrence is common. In young adults, long-term outcomes are determined more by adherence and successful transitional care than by variceal severity. Structured transitional programs are essential for preventing loss to follow-up and improving survival in pediatric-onset portal hypertension.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"735-743"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to "Aspirin for Primary Prevention in Metabolic Dysfunction-Associated Steatotic Liver Disease". 对“阿司匹林用于代谢功能障碍相关脂肪变性肝病的一级预防”的回应。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-01 Epub Date: 2026-01-22 DOI: 10.1111/hepr.70123

Tsubasa Tsutsumi, Michael R Charlton, Takumi Kawaguchi, Mary E Rinella

引用次数: 0

Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients. 丙型肝炎患者直接作用药物（DAA）初始失败后的再治疗。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-01 Epub Date: 2026-01-29 DOI: 10.1111/hepr.70128

Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto

{"title":"Retreatment of Direct Acting Agents (DAAs) After Initial DAA Failure in Hepatitis C Patients.","authors":"Nobuharu Tamaki, Masayuki Kurosaki, Hironori Ochi, Hideki Fujii, Yuichiro Suzuki, Takuya Sho, Hayato Hikita, Hiroyuki Marusawa, Yasuhiro Asahina, Namiki Izumi, Tatsuya Kanto","doi":"10.1111/hepr.70128","DOIUrl":"10.1111/hepr.70128","url":null,"abstract":"Background and aims: Glecaprevir/pibrentasvir (GLE/PIB) and sofosbuvir/ledipasvir (SOF/LDV) are widely used as first-line direct-acting antiviral (DAA) regimens for chronic hepatitis C, achieving high virus eradication rates. However, a small proportion of patients experience treatment failure, and the optimal retreatment strategies for such cases remain unclear. This nationwide, multicenter, prospective study aimed to evaluate the efficacy of retreatment regimens in patients who failed initial DAA therapy.Methods: A total of 330 patients were enrolled, including 117 with prior GLE/PIB failure and 213 with prior SOF/LDV failure. The primary outcome was sustained virologic response at 12 weeks after retreatment (SVR12). Retreatment regimens included 12 weeks of GLE/PIB, sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV), or SOF/LDV.Results: Among patients retreated after GLE/PIB failure, SVR12 rates were 99.0% (98/99) with SOF/VEL + RBV, 92.3% (12/13) with GLE/PIB 12 weeks, and 100% (5/5) with SOF/LDV, with no significant differences among regimens. Among patients retreated after SOF/LDV failure, SVR12 rates were 100% (12/12) with SOF/VEL + RBV, 99.5% (197/198) with GLE/PIB 12 weeks, and 66.7% (2/3) with SOF/LDV. Retreatment of SOF/VEL + RBV or GLE/PIB demonstrated high therapeutic efficacy in patients with prior SOF/LDV failure. One patient who relapsed after GLE/PIB 8-week therapy and harbored a P32del mutation achieved SVR12 with SOF/VEL + RBV retreatment.Conclusions: Retreatment with SOF/VEL + RBV, GLE/PIB for 12 weeks, or SOF/LDV achieved high SVR12 rates, indicating that effective viral eradication is feasible using currently available DAA regimens even after prior treatment failure.","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":" ","pages":"778-783"},"PeriodicalIF":3.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146085642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Steatotic Liver Disease and the "Point of No Return" in the Development of Metabolic Disorders. 脂肪变性肝病和代谢紊乱发展的“不归路”。

IF 3.4 3区医学

Hepatology Research Pub Date : 2026-05-01 Epub Date: 2026-02-04 DOI: 10.1111/hepr.70137

Tsutomu Nishida, Satoru Okabe, Akira Doi, Kengo Matsumoto

引用次数: 0